Company intelligence / Profile preview
VERDI Solutions
- Ownership
- Private
- Development stage
- Preclinical
Overview
VERDI Solutions has developed a proprietary AI-powered platform for designing personalized peptide vaccines targeting unique tumor profiles. The technology has been used under compassionate use in Europe to treat three patients with bone metastases (two breast cancer, one gastric cancer), resulting in significant pain relief and improved quality of life. Broader clinical validation is pending; plans are underway to initiate formal clinical trials in the United States through a partnership with Anixa Biosciences[3][4][6][7].
- Therapeutic areas
- Oncology
- Modalities
- Peptide vaccines (personalized and off-the-shelf)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on VERDI Solutions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VERDI Solutions.